---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050164"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:05:52.486592+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance

## Summary
- Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.
- Adjusted EBITDA $24.6M, up 39% from $17.7M; non-GAAP EPS $0.16 vs $0.12.
- Stent grafts +38%, On-X +25%, preservation +5%, BioGlue +2% YoY.
- Enrolled first patient in ARTIZEN IDE trial for Arcevo; refinanced credit to 2031 with $150M delayed draw.
- Raises FY 2025 revenue guidance to $439-$445M (prev $435-$443M) and EBITDA to $88-$91M (prev $86-$91M).

## SEC filing metadata
- accession: 0001628280-25-050164
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000162828025050164/0001628280-25-050164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000162828025050164/aort-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050164
- JSON: https://secwatch.observer/filing/0001628280-25-050164.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.